ArticleUltrasound in medicine & biology2026
MRI for the Assessment of Histotripsy Ablation in a Canine Osteosarcoma Comparative Oncology Model.
Article in Ultrasound in medicine & biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- The first limb-sparing use of histotripsy for canine osteosarcoma.Scientific reports · 2026Article
- Histotripsy treatment reduces tumor burden and extends survival in an orthotopic mouse model of osteosarcoma.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveTo explore the use of MRI for evaluation of mechanical focused ultrasound (histotripsy) ablation in spontaneous canine osteosarcoma (OS) as a comparative oncology model of human OS.
methodsA retrospective analysis was conducted on MR images from a veterinary clinical trial, with the purpose of using canine OS as a preclinical model in which to study human OS. Eight dogs received histotripsy treatment to a portion of their tumor, with pre- and post-treatment MRI (pre- and post-contrast T1- and T2-weighted). Dogs then received standard-of-care surgical resection. Qualitative assessments included characterization of ablation on MRI, gross anatomy, and histopathology. Quantitative assessments included measurements of ablation on MRI and gross anatomy, as well as scoring tumor bone production in untreated tumor on MRI and histopathology to compare tumor composition assessments across modalities.
resultsContrast-enhanced sequences with and without subtraction reliably visualized histotripsy ablation. For all dogs, the ablation zone was visible as a nonenhancing, hypointense region. There was a significant decrease in normalized mean signal intensity of the targeted tumor region from pre- to post-histotripsy. No significant differences were found between MRI and gross measurements of ablation dimensions and volume. Histopathology confirmed ablation in the targeted regions as identified grossly and on MRI, and tumor bone composition assessments on MRI and histopathology had a significant positive correlation.
conclusionsMRI is a valuable tool for the assessment of histotripsy ablation in OS and builds upon the potential of histotripsy as a non-invasive therapy for bone tumors in dogs and humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.